1-20 of 23
Nicholas J. Vogelzang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A019: Phase 1, first-in-human, dose-expansion study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma

Andrew J. Wagner, Gregory M. Cote, Donald Richards, Nicholas J. Vogelzang, William J. Edenfield, Mitchell E. Gross, Lynn Mar, Gil D. Fine, Edward Dow, John A. Charlson
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A019.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A019
Published: 15 September 2022
View article titled, Abstract A019: Phase 1, first-in-human, dose-expansion study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma
Journal Articles

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-21-3089
Published: 13 May 2022
View article titled, Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Open the PDF for Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials in another window
Includes: Supplementary data
Journal Articles

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Andrea Loehr, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H. Bryce, Ray McDermott, Brieuc Sautois, Nicholas J. Vogelzang, Richard M. Bambury, Eric Voog, Jingsong Zhang, Josep M. Piulats, Arif Hussain, Charles J. Ryan, Axel S. Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Celestia S. Higano, Laurence E. Krieger, Cora N. Sternberg, Simon P. Watkins, Darrin Despain, Andrew D. Simmons, Melanie Dowson, Tony Golsorkhi, Simon Chowdhury, Wassim Abida
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6677–6686.
https://doi.org/10.1158/1078-0432.CCR-21-2199
Published: 15 December 2021
View article titled, Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
Open the PDF for Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study in another window
Includes: Supplementary data
Journal Articles

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Amir Goldkorn, Catherine Tangen, Melissa Plets, Gareth J. Morrison, Alexander Cunha, Tong Xu, Jacek K. Pinski, Sue A. Ingles, Timothy Triche, Andrea L. Harzstark, Manish Kohli, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David J. McConkey, Primo N. Lara, Jr, Maha H.A. Hussain, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson, Jr, Neeraj Agarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 1967–1973.
https://doi.org/10.1158/1078-0432.CCR-20-3587
Published: 01 April 2021
View article titled, Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)
Open the PDF for Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216) in another window
Journal Articles

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Wassim Abida, David Campbell, Akash Patnaik, Jeremy D. Shapiro, Brieuc Sautois, Nicholas J. Vogelzang, Eric G. Voog, Alan H. Bryce, Ray McDermott, Francesco Ricci, Julie Rowe, Jingsong Zhang, Josep Maria Piulats, Karim Fizazi, Axel S. Merseburger, Celestia S. Higano, Laurence E. Krieger, Charles J. Ryan, Felix Y. Feng, Andrew D. Simmons, Andrea Loehr, Darrin Despain, Melanie Dowson, Foad Green, Simon P. Watkins, Tony Golsorkhi, Simon Chowdhury
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2487–2496.
https://doi.org/10.1158/1078-0432.CCR-20-0394
Published: 01 June 2020
View article titled, Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Open the PDF for Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study in another window
Includes: Supplementary data
Journal Articles

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

Emmanuel S. Antonarakis, Adam S. Kibel, Evan Y. Yu, Lawrence I. Karsh, Aymen Elfiky, Neal D. Shore, Nicholas J. Vogelzang, John M. Corman, Frederick E. Millard, Johnathan C. Maher, Nancy N. Chang, Todd DeVries, Nadeem A. Sheikh, Charles G. Drake
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (10): 2451–2459.
https://doi.org/10.1158/1078-0432.CCR-16-1780
Published: 14 May 2017
View article titled, Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
Open the PDF for Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig, Franklin Chu, Roberto Pili, Joseph J. Stephenson, Nicholas J. Vogelzang, Alan J. Koletsky, Luke T. Nordquist, William J. Edenfield, Khalid Mamlouk, Karen J. Ferrante, Mary-Ellen Taplin
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1356–1363.
https://doi.org/10.1158/1078-0432.CCR-15-1432
Published: 14 March 2016
View article titled, Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Open the PDF for Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, Donald Thornton
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (13): 3581–3588.
https://doi.org/10.1158/1078-0432.CCR-13-2686
Published: 30 June 2014
View article titled, A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Open the PDF for A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer in another window
Journal Articles

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

Geoffrey I. Shapiro, Raoul Tibes, Michael S. Gordon, Bryan Y. Wong, Joseph Paul Eder, Mitesh J. Borad, David S. Mendelson, Nicholas J. Vogelzang, Bruno R. Bastos, Glen J. Weiss, Cristian Fernandez, William Sutherland, Hitoshi Sato, William E. Pierceall, David Weaver, Scott Slough, Ernesto Wasserman, Donald W. Kufe, Daniel Von Hoff, Takumi Kawabe, Sunil Sharma
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3431–3442.
https://doi.org/10.1158/1078-0432.CCR-10-2345
Published: 15 May 2011
View article titled, Phase I Studies of CBP501, a G<sub>2</sub> Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
Open the PDF for Phase I Studies of CBP501, a G<sub>2</sub> Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

Tanya B. Dorff, Bryan Goldman, Jacek K. Pinski, Philip C. Mack, Primo N. Lara, Jr., Peter J. Van Veldhuizen, Jr., David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Jr., Maha H.A. Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 3028–3034.
https://doi.org/10.1158/1078-0432.CCR-09-3122
Published: 31 May 2010
View article titled, Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Open the PDF for Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer in another window
Journal Articles

Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study

Charles J. Ryan, Susan Halabi, San-San Ou, Nicholas J. Vogelzang, Philip Kantoff, Eric J. Small, for the Cancer and Leukemia Group B
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2030–2037.
https://doi.org/10.1158/1078-0432.CCR-06-2344
Published: 02 April 2007
View article titled, Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study
Open the PDF for Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study in another window
Journal Articles

Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee

Eric J. Small, Susan Halabi, Phillip Kantoff, Anthony D'Amico, Walter Stadler, W. Kevin Kelley, James Mohler, Dean Bajorin, Nicholas J. Vogelzang
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (11): 3596s–3600s.
https://doi.org/10.1158/1078-0432.CCR-06-9005
Published: 01 June 2006
View article titled, Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee
Open the PDF for Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee in another window
Journal Articles

A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

Primo N. Lara, Jr., Walter M. Stadler, Jeff Longmate, David I. Quinn, Jason Wexler, Marta Van Loan, Przemyslaw Twardowski, Paul H. Gumerlock, Nicholas J. Vogelzang, Everett E. Vokes, Heinz Josef Lenz, James H. Doroshow, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (5): 1556–1563.
https://doi.org/10.1158/1078-0432.CCR-05-2074
Published: 06 March 2006
View article titled, A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
Open the PDF for A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases in another window
Journal Articles

Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study

Robert W. Ross, Susan Halabi, San-San Ou, Barur R. Rajeshkumar, Bruce A. Woda, Nicholas J. Vogelzang, Eric J. Small, Mary-Ellen Taplin, Philip W. Kantoff
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (22): 8109–8113.
https://doi.org/10.1158/1078-0432.CCR-05-1250
Published: 18 November 2005
View article titled, Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study
Open the PDF for Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study in another window
Journal Articles

The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480

Daniel J. George, Susan Halabi, Timothy F. Shepard, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, Philip W. Kantoff
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (5): 1815–1820.
https://doi.org/10.1158/1078-0432.CCR-04-1560
Published: 08 March 2005
View article titled, The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480
Open the PDF for The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 in another window
Journal Articles

Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies

Christopher W. Ryan, Nicholas J. Vogelzang, Everett E. Vokes, Hedy L. Kindler, Samir D. Undevia, Rod Humerickhouse, Amy K. André, Qiang Wang, Robert A. Carr, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4406–4411.
https://doi.org/10.1158/1078-0432.CCR-04-0083
Published: 06 July 2004
View article titled, Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies
Open the PDF for Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies in another window
Journal Articles

A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer

Walter M. Stadler, Dingcai Cao, Nicholas J. Vogelzang, Christopher W. Ryan, Kristin Hoving, Russell Wright, Theodore Karrison, Everett E. Vokes
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3365–3370.
https://doi.org/10.1158/1078-0432.CCR-03-0404
Published: 24 May 2004
View article titled, A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer
Open the PDF for A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer in another window
Journal Articles

Safety and Biological Activity of Repeated Doses of Recombinant Human Flt3 Ligand in Patients with Bone Scan-Negative Hormone-Refractory Prostate Cancer

Celestia S. Higano, Nicholas J. Vogelzang, Jeffrey A. Sosman, Anyang Feng, Dania Caron, Eric J Small
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (4): 1219–1225.
https://doi.org/10.1158/1078-0432.CCR-1404-02
Published: 20 February 2004
View article titled, Safety and Biological Activity of Repeated Doses of Recombinant Human Flt3 Ligand in Patients with Bone Scan-Negative Hormone-Refractory Prostate Cancer
Open the PDF for Safety and Biological Activity of Repeated Doses of Recombinant Human Flt3 Ligand in Patients with Bone Scan-Negative Hormone-Refractory Prostate Cancer in another window
Journal Articles

Importance of Serum Hemoglobin in Hormone Refractory Prostate Cancer

Robin T. Vollmer, Philip W. Kantoff, Nancy A. Dawson, Nicholas J. Vogelzang
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (4): 1049–1053.
Published: 01 April 2002
View article titled, Importance of Serum Hemoglobin in Hormone Refractory Prostate Cancer
Open the PDF for Importance of Serum Hemoglobin in Hormone Refractory Prostate Cancer in another window
Journal Articles

Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480

Daniel J. George, Susan Halabi, Timothy F. Shepard, Nicholas J. Vogelzang, Daniel F. Hayes, Eric J. Small, Philip W. Kantoff
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 1932–1936.
Published: 01 July 2001
View article titled, Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480
Open the PDF for Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480 in another window